About Grannus Therapeutics
Grannus Therapeutics is a private company based in Indianapolis, Indiana, incorporated in 2020 in United States. It has reported $1,750,000 raised in two offerings on Form D since January 2022. Its chief executive is John Foglesong.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2023 | Jan 12, 2024 | $800,000fully sold | 9 | $88,889 | DebtRule 506(b) | Form D ↗ |
| Jan 12, 2022 | Jan 21, 2022 | $950,000of $1.0M target | 11 | $86,364 | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $1,750,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Grannus Therapeutics's Form D filed Jan 12, 2024.
JF
John Foglesong
CEO and director
BB
Brian Blagg
Director
Earlier filings also listed James Thompson (director, last listed Jan 2022).